MOLN Molecular Partners

Molecular Partners to Present at SVB Leerink Global Healthcare Conference

Molecular Partners to Present at SVB Leerink Global Healthcare Conference

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that its Chief Executive Officer, Patrick Amstutz, Ph.D., will participate in the SVB Leerink Global Healthcare conference (Virtual).

Conference Presentation Details:

SVB Leerink Global Healthcare Conference Wednesday, February 15, 2023, at 12:00 pm ET (6:00 pm CET)

A webcast and replay of the presentation will be made available on the Molecular Partners .

About Molecular Partners AG:

Molecular Partners AG is a clinical-stage biotech company developing DARPin therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics in the areas of oncology and infectious disease and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas. ; Find us on Twitter - @MolecularPrtnrs

For further details, please contact:

Seth Lewis, Head of Investor Relations & Strategy

Concord, Massachusetts, U.S.

Tel:

Antonio Ligi, Head of Communications

Zürich-Schlieren, Switzerland

Tel: 1



EN
10/02/2023

Underlying

MOLNMolecular Partners

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Molecular Partners

 PRESS RELEASE
Free
MOLN Molecular Partn...

Molecular Partners Forms Scientific Advisory Board to Accelerate Devel...

Molecular Partners Forms Scientific Advisory Board to Accelerate Development of Targeted Radiotherapeutics Chaired by globally renowned nuclear medicine expert Prof. Ken Herrmann, M.D. Other Board members James Cook, Jason Lewis, Ph.D., and Michael Morris, M.D. bring significant clinical and industry expertise, supporting transition from early clinical validation to strategic development ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drug...

December 11, 2025 1 EN
 PRESS RELEASE
Free
MOLN Molecular Partn...

Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial...

Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial of MP0533 in AML at ASH Annual Meeting Poster outlines clinical benefit with acceptable safety profile across 9 tested dosing regimensAccelerated step-up dosing and higher dosing frequency is feasible and results in increased exposure Six of eight responders presented with low bone marrow blast counts at baseline, supporting further investigation in this patient population most likely to benefit from MP0533 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant...

December 7, 2025 1 EN
Free Trial
MOLN Molecular Partn...

Molecular Partners AG: 1 director

A director at Molecular Partners AG sold 35,000 shares at 0.000CHF and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...

MOLN MOLECULAR PARTNERS
11/27/25 November 27, 2025 1 EN
 PRESS RELEASE
Free
MOLN Molecular Partn...

Molecular Partners Presents New Data for DLL3 Targeting Radiotherapy M...

Molecular Partners Presents New Data for DLL3 Targeting Radiotherapy MP0712 at TRP Summit Europe 2025, Highlighting Initial Human Images and Mechanism of Action Case study with first patient images of half-life engineered MP0712 from compassionate care use show specific uptake in primary tumors and metastatic lesions MP0712 Radio-DARPin leverages rapid internalization & replenishment of DLL3 to achieve high accumulation in tumor cells Phase 1 IND for MP0712 filed, clinical trial initiation expected before end-2025 in US with initial data expected in 2026 Molecular Partners to host confer...

November 12, 2025 1 EN
 PRESS RELEASE
Free
MOLN Molecular Partn...

Molecular Partners presents additional preclinical proof-of-concept da...

Molecular Partners presents additional preclinical proof-of-concept data on logic-gated CD3 Switch-DARPin at SITC 2025 Poster presentation outlines potential of CD3 Switch-DARPin T cell engager (TCE) using an AND-gate to overcome limitations of other TCEs Demonstrated selective T cell cytotoxicity against cells co-expressing tumor-associated antigens MSLN and EpCAM Induced significant tumor regression in vivo without causing systemic cytokine release, indicating favorable safety profile ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcem...

November 3, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch